You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Médicaments

La bibliothèque de médicaments donne accès à des renseignements sur plus de 100 médicaments anticancéreux commercialisés au Canada.

Trouvez plus d’information sur la sécurité  dans le document patient supplémentaire Comment prendre vos médicaments oraux contre le cancer de manière sécuritaire.

Displaying Drugs List

172 Items
Other Name(s): Tecentriq™
Funding:
New Drug Funding Program
  • Atezolizumab – Advanced or Metastatic Non-Small Cell Lung Cancer
Updated
Feb 2020
Other Name(s): Bavencio(TM)
Funding:
New Drug Funding Program
  • Avelumab - Metastatic Merkel Cell Carcinoma
May 2019
Other Name(s): Inlyta®
Funding:
Exceptional Access Program
  • aXitinib - For the treatment of metastatic renal cell carcinoma of clear cell histology (second-line), according to clinical criteria
Jun 2019
Other Name(s): Vidaza® (Celgene)
Funding:
New Drug Funding Program
  • Azacitidine - Acute Myeloid Leukemia (AML)
  • Azacitidine - Intermediate-2 and high-risk myelodysplastic syndrome (MDS)
Nov 2017
Other Name(s): Treanda® (Lundbeck Canada Inc.)
Funding:
New Drug Funding Program
  • Bendamustine - First Line - Chronic Lymphocytic Leukemia
  • Bendamustine - Relapsed_Refractory - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
  • Bendamustine - First Line - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Apr 2017
Other Name(s): Avastin®; Mvasi™; Zirabev™
Funding:
New Drug Funding Program
  • Bevacizumab (Biosimilar) - First Line - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
  • Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
  • Bevacizumab (Biosimilar) with Paclitaxel and Carboplatin - Front-line Treatment (Previously Untreated) Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
  • Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Dec 2019
Other Name(s): Casodex® (multiple brands available)
Funding:
ODB - General Benefit
  • bicalutamide
Sep 2019
Sep 2019
Other Name(s): Blincyto®
Funding:
New Drug Funding Program
  • Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia
  • Blinatumomab – Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia
  • Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)
  • Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia (Ph- BCP-ALL)
Updated
Feb 2020
Other Name(s): Velcade®
Funding:
New Drug Funding Program
  • Bortezomib - Previously Untreated - Multiple Myeloma
  • Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
  • Bortezomib - Relapsed or Refractory Multiple Myeloma
Jul 2019
Other Name(s): Bosulif®
Funding:
Exceptional Access Program
  • bosutinib - For the treatment of patients with chronic, accelerated or blast phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML), according to specific criteria.
Jun 2019
Other Name(s): Adcetris®
Funding:
New Drug Funding Program
  • Brentuximab Vedotin – Relapsed or Refractory Hodgkin Lymphoma
  • Brentuximab Vedotin – Systemic Anaplastic Large Cell Lymphoma
  • Brentuximab Vedotin – Consolidation Post-Autologous Stem Cell Transplant (ASCT) for Hodgkin Lymphoma
Dec 2019